Literatur
-
1
Berendes E, Van Aken H, Raufhake C, Schmidt C, Assmann G, Walter M.
Differential secretion
of atrial and brain natriuretic peptide in critically ill patients.
Anesth
Analg.
2001;
93
676-682
-
2
Berger R, Huelsman M, Strecker K. et al .
B-type natriuretic peptide predicts sudden
death in patients with chronic heart failure.
Circulation.
2002;
105
2392-2397
-
3
Cataliotti A, Malatino L S, Jougasaki M. et al .
Circulating natriuretic peptide
concentrations in patients with end-stage renal disease: role of
brain natriuretic peptide as a biomarker for ventricular remodeling.
Mayo
Clin Proc.
2001;
76
1111-1119
-
4
Chen H H, Burnett J C.
Natriuretic
peptides in the pathophysiology of congestive heart failure.
Curr
Cardiol Rep.
2000;
2
198-205
-
5
Cowie M R, Struthers A D, Wood D A. et al .
Value of natriuretic peptides in
assessment of patients with possible new heart failure in primary care.
Lancet.
1997;
350
1349-1353
-
6
Cowie M R, Wood D A, Coats A J. et al .
Incidence and aetiology
of heart failure: a population-based study.
Eur Heart
J.
1999;
20
421-428
-
7
Dao Q, Krishnaswamy P, Kazanegra R. et al .
Utility
of B-type natriuretic peptide in the diagnosis of congestive heart
failure in an urgent-care setting.
J Am Coll Cardiol.
2001;
37
379-385
-
8
Davis M, Espiner E, Richards G. et al .
Plasma brain natriuretic peptide in assessment
of acute dyspnoea.
Lancet.
1994;
343
440-444
-
9
de Lemos J A, Morrow D A, Bentley J H. et al .
The prognostic value of
B-type natriuretic peptide in patients with acute coronary syndromes.
N
Engl J Med.
2001;
345
1014-1021
-
10
Del Ry S, Giannessi D, Clerico A.
Plasma
brain natriuretic peptide measured by fully-automated immunoassay
and by immunoradiometric assay compared.
Clin Chem Lab
Med.
2001;
39
446-450
-
11
Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J.
Head-to-head comparison
of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide
and N-terminal pro-atrial natriuretic peptide in diagnosing left
ventricular dysfunction.
Clin Chim Acta.
2001;
310
193-197
-
12
Hirata Y, Matsumoto A, Aoyagi T. et al .
Measurement of plasma brain natriuretic
peptide level as a guide for cardiac overload.
Cardiovasc Res.
2001;
51
585-591
-
13
Hobbs F D, Davis R C, Roalfe A K, Hare R, Davies M K, Kenkre J E.
Reliability
of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart
failure: cohort study in representative and high risk community
populations.
BMJ.
2002;
324
1498
-
14
Hunt P J, Richards A M, Nicholls M G, Yandle T G, Doughty R N, Espiner E A.
Immunoreactive
amino-terminal pro-brain natriuretic peptide (NT- PROBNP): a new
marker of cardiac impairment.
Clin Endocrinol (Oxf).
1997;
47
287-296
-
15
Hunt P J, Yandle T G, Nicholls M G, Richards A M, Espiner E A.
The amino-terminal portion of
pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma.
Biochem
Biophys Res Commun.
1995;
214
1175-1183
-
16
Hunt S A, Baker D W, Chin M H. et al .
ACC/AHA guidelines
for the evaluation and management of chronic heart failure in the
adult: executive summary. A report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee to revise
the 1995 Guidelines for the Evaluation and Management of Heart Failure).
J
Am Coll Cardiol.
2001;
38
2101-2113
-
17
Jensen K T, Carstens J, Ivarsen P, Pedersen E B.
A new, fast
and reliable radioimmunoassay of brain natriuretic peptide in human
plasma. Reference values in healthy subjects and in patients with
different diseases.
Scand J Clin Lab Invest.
1997;
57
529-540
-
18
Karl J, Borgya A, Gallusser A. et al .
Development of a novel, N-terminal-proBNP
(NT-proBNP) assay with a low detection limit.
Scand J Clin
Lab Invest Suppl.
1999;
230
177-181
-
19
Kazanegra R, Cheng V, Garcia A. et al .
A rapid test for B-type natriuretic peptide
correlates with falling wedge pressures in patients treated for
decompensated heart failure: a pilot study.
J Card Fail.
2001;
7
21-29
-
20
Kjaer A, Hesse B.
Heart failure and neuroendocrine
activation: diagnostic, prognostic and therapeutic perspectives.
Clin
Physiol.
2001;
21
661-672
-
21
Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W.
Role of brain natriuretic
peptide in risk stratification of patients with congestive heart
failure.
J Am Coll Cardiol.
2001;
38
1934-1941
-
22
Krishnaswamy P, Lubien E, Clopton P. et al .
Utility of B-natriuretic peptide levels
in identifying patients with left ventricular systolic or diastolic
dysfunction.
Am J Med.
2001;
111
274-279
-
23
Latini R, Masson S, Anand I. et al .
Effects of valsartan on circulating brain natriuretic peptide and
norepinephrine in symptomatic chronic heart failure: the Valsartan
Heart Failure Trial (Val-HeFT).
Circulation .
2002;
106
2454-2458
-
24
Lubien E, DeMaria A, Krishnaswamy P. et al .
Utility of B-natriuretic peptide in detecting
diastolic dysfunction: comparison with Doppler velocity recordings.
Circulation.
2002;
105
595-601
-
25
Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M.
Plasma brain
natriuretic peptide as a biochemical marker of high left ventricular
end-diastolic pressure in patients with symptomatic left ventricular
dysfunction.
Am Heart J.
1998;
135
825-832
-
26
Maisel A S, Krishnaswamy P, Nowak R M. et al .
Rapid measurement of B-type
natriuretic peptide in the emergency diagnosis of heart failure.
N
Engl J Med.
2002;
347
161-167
-
27
McCullough P A, Nowak R M, McCord J. et al .
B-type natriuretic peptide and clinical
judgment in emergency diagnosis of heart failure: analysis from
Breathing Not Properly (BNP) Multinational Study.
Circulation.
2002;
106
416-422
-
28
McDonagh T A, Cunningham A D, Morrison C E. et al .
Left ventricular dysfunction,
natriuretic peptides, and mortality in an urban population.
Heart.
2001;
86
21-26
-
29
McDonagh T A, Robb S D, Murdoch D R. et al .
Biochemical detection of left-ventricular
systolic dysfunction.
Lancet.
1998;
351
9-13
-
30
McNairy M, Gardetto N, Clopton P. et al .
Stability of B-type natriuretic peptide
levels during exercise in patients with congestive heart failure:
implications for outpatient monitoring with B-type natriuretic peptide.
Am
Heart J.
2002;
143
406-411
-
31
Morrison L K, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A.
Utility of a rapid B-natriuretic
peptide assay in differentiating congestive heart failure from lung
disease in patients presenting with dyspnea.
J Am Coll
Cardiol.
2002;
39
202-209
-
32
Mukoyama M, Nakao K, Obata K. et
al .
Augmented secretion of brain natriuretic peptide
in acute myocardial infarction.
Biochem Biophys Res Commun.
1991;
180
431-436
-
33
Murdoch D R, Byrne J, McDonagh T, Morton J J, McMurray J J.
Measurement of brain natriuretic peptide.
Lancet.
1996;
348
1589
-
34
Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider C A.
The
rank of natriuretic peptides NT-pro-BNP and BNP for the estimation
of left-ventricular volume and function.
Dtsch Med Wochenschr.
2002;
127
2605-2609
-
35
Remme W J, Swedberg K.
Guidelines for the
diagnosis and treatment of chronic heart failure.
Eur
Heart J.
2001;
22
1527-1560
-
36
Richards A M, Doughty R, Nicholls M G. et al. Australia-New Zealand Heart Failure Group .
Neurohumoral
prediction of benefit from carvedilol in ischemic left ventricular
dysfunction.
Circulation.
1999;
99
786-792
-
37
Sayama H, Nakamura Y, Saito N, Kinoshita M, Suda M.
Relationship between
left ventricular geometry and brain natriuretic peptide levels in
elderly subjects.
Gerontology.
2000;
46
71-77
-
38
Smith H, Pickering R M, Struthers A, Simpson I, Mant D.
Biochemical diagnosis
of ventricular dysfunction in elderly patients in general practice:
observational study.
BMJ.
2000;
320
906-908
-
39
Smith R A.
Breast
cancer screening among women younger than age 50: a current assessment
of the issues.
CA Cancer J Clin.
2000;
50
312-336
-
40
Sudoh T, Kangawa K, Minamino N, Matsuo H.
A new natriuretic peptide
in porcine brain.
Nature.
1988;
332
78-81
-
41
Talwar S, Squire I B, Downie P F, Davies J E, Ng L L.
Plasma N terminal pro-brain natriuretic
peptide and cardiotrophin 1 are raised in unstable angina.
Heart.
2000;
84
421-424
-
42
Troughton R W, Frampton C M, Yandle T G, Espiner E A, Nicholls M G, Richards A M.
Treatment
of heart failure guided by plasma aminoterminal brain natriuretic
peptide (N-BNP) concentrations.
Lancet.
2000;
355
1126-1130
-
43
Vasan R S, Benjamin E J, Larson M G. et al .
Plasma natriuretic peptides for
community screening for left ventricular hypertrophy and systolic
dysfunction: the framingham heart study.
JAMA.
2002;
288
1252-1259
Priv.-Doz. Dr. med. Christian Alfons Schneider
Klinik III für
Innere Medizin, Universität zu Köln
Josef-Stelzmann Str. 9
50924 Köln
Telefon: 0221/4786207
Fax: 0221/4783763
eMail: christian.schneider@medizin.uni-koeln.de
